Skip to main content
Fig. 2 | BMC Urology

Fig. 2

From: Calcitriol-mediated hypercalcemia as an immune-related adverse event in a patient receiving nivolumab and ipilimumab for metastatic renal cell carcinoma, case report

Fig. 2

This graph demonstrates the changes in levels of calcium (shown in gray), 1, 25(OH) D (shown in blue), and 25(OH) D (shown in orange) throughout the patient’s hospitalization as various treatments were provided as labeled above. The X axis represents time measured in days. The left Y axis illustrates vitamin D levels in mg/dL. The right Y axis demonstrates the calcium levels in mg/dL. The green dashed lines indicate the start dates for the various treatments described above including steroids (prednisone), zoledronic acid, calcitonin, and immunotherapy (nivolumab and ipilimumab re-challenge)

Back to article page

BMC Urology

ISSN: 1471-2490

Contact us